Why Is ADC Therapeutics Stock Falling Thursday? - ADC Therapeutics (NYSE:ADCT)
ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed/refractory DLBCL. The combo met the primary endpoint for progression-free survival (6.1 vs 4.7 months vs R-GemOx) and showed no detrimental overall survival impact, with higher response rates (58.1% vs 45.2%) and longer complete responses. Safety differed, with more serious events and Grade 5 events in the ZYNLONTA arm. Shares fell 49.68% to $1.55 premarket.
How this was made
The 30-second read
Why it matters
The market reaction appears driven by the combination’s safety/tolerability profile (higher serious AEs, discontinuations, and Grade 5 events) despite meeting the primary PFS endpoint and showing improved response metrics. The FDA discussion timeline (pre-sBLA August; sBLA Q4 2026) sets the next decision points.
Market read
A single-stock catalyst: Phase 3 topline success on PFS with no OS detriment, but safety concerns and higher severe events likely explain the outsized premarket drop.
What to watch
Control-arm OS analysis was confounded by earlier switching/new therapies; traders may be over-penalizing safety without fully adjusting for that bias and age-related Grade 5 concentration (≥75).
Background
LOTIS-5 is ADC Therapeutics’ Phase 3 confirmatory study for ZYNLONTA (loncastuximab tesirine) plus rituximab in relapsed/refractory DLBCL, with a planned regulatory path via pre-sBLA and sBLA.
Ticker impact
ADC Therapeutics reported LOTIS-5 Phase 3 topline results where ZYNLONTA plus rituximab met the primary PFS endpoint, driving a sharp premarket selloff.
Choppy-to-down bias near-term as investors weigh Grade 5/serious AEs and the path to sBLA/FDA discussion.
The article highlights endpoint success and no OS detriment, yet notes higher serious AEs, discontinuations, and Grade 5 events in the test arm—factors that can overwhelm efficacy in a high-risk biotech tape.
Market effects
Reinforces that ADC/lymphoma combinations can clear PFS endpoints yet still face valuation pressure from safety and regulatory-risk framing.
Primarily US small/mid-cap biotech sentiment; limited direct regional spillover beyond healthcare risk appetite.
US FDA next-steps (pre-sBLA in August, sBLA Q4 2026) can influence global investor expectations for similar lymphoma ADC programs.
Counterpoint
Endpoint success with no OS detriment and higher complete response rates could be underweighted versus the safety headline, implying potential mean-reversion if investors focus on efficacy durability.
Key entities
- companyADC Therapeutics
Subject of the article; released LOTIS-5 topline efficacy/safety and outlined FDA meeting and sBLA timing.
- drugZYNLONTA
Investigational regimen component tested with rituximab in LOTIS-5.
- regulatorU.S. FDA
Next-step regulator for pre-sBLA discussion and subsequent sBLA submission.
